Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial.

ABSTRACT:

Background

Strict eligibility criteria for participation in randomized clinical trials (RCTs) often limit the generalizability of data when applied to a more heterogeneous real-world population. Thus, evidence generated directly from real-world populations, including subgroups underrepresented in RCTs, can help inform routine clinical practice. POLARIS (NCT03280303), a prospective, observational, multicenter, cohort study, evaluated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) receiving palbociclib + endocrine therapy (ET) in routine care.

Methods

Demographics, baseline characteristics, and treatment patterns were summarized descriptively. Real-world response and clinical benefit rates, rea

SUBMITTER: Tripathy D 

PROVIDER: S-EPMC12311288 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature